Hemispherx Biopharma Inc. Daily Stock Analysis

Daily Stock Analysis, HEB, Hemispherx Biopharma Inc, priceseries

Hemispherx Biopharma Inc. Daily Stock Analysis
Stock Information
Open
1.97
Close
1.80
High
1.97
Low
1.78
Previous Close
1.96
Daily Price Gain
-0.16
YTD High
15.19
YTD High Date
Apr 30, 2019
YTD Low
1.51
YTD Low Date
Sep 3, 2019
YTD Price Change
-6.12
YTD Gain
-77.27%
52 Week High
15.19
52 Week High Date
Apr 30, 2019
52 Week Low
1.51
52 Week Low Date
Sep 3, 2019
52 Week Price Change
-7.88
52 Week Gain
-81.40%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 20. 2017
25.08
May 1. 2017
26.92
7 Trading Days
7.33%
Link
LONG
Oct 6. 2017
14.52
Oct 9. 2017
15.32
1 Trading Days
5.54%
Link
LONG
Jan 5. 2018
15.84
Jan 19. 2018
21.04
9 Trading Days
32.80%
Link
LONG
Jan 7. 2019
8.80
Jan 30. 2019
9.79
16 Trading Days
11.27%
Link
LONG
Apr 26. 2019
6.60
May 2. 2019
7.26
4 Trading Days
10.00%
Link
Company Information
Stock Symbol
HEB
Exchange
NYSE MKT
Company URL
http://www.hemispherx.net
Company Phone
215-988-0080
CEO
Thomas Kenwood Equels
Headquarters
Pennsylvania
Business Address
1617 JFK BLVD, SUITE #500, ONE PENN CENTER, PHILADELPHIA, PA 19103
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000946644
About

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.

Description

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading